SynAct gets US Notice of Allowance for resomelagon tablet patent
SynAct Pharma received a USPTO Notice of Allowance for a resomelagon tablet patent. Protection under the patent is expected to run to June 2042.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
TradingView reports that the US Patent and Trademark Office has issued a Notice of Allowance to Swedish biotech SynAct Pharma AB for patent application No. 18/065,702. The application covers an immediate-release oral solid dosage form of resomelagon (AP1189 acetate), the company's most advanced drug candidate, which is in clinical testing.
Once the issue fee is paid, the patent is expected to be granted within a few weeks. SynAct says it would extend protection to June 2042, with patent term adjustment still undetermined. The company already holds two US patents covering the crystal form of the compound, one of which runs to July 2, 2044 after adjustment.
why it matters
For investors this is an incremental step in building intellectual property around the lead asset rather than a direct business event. Clinical data and regulatory progress remain the main drivers, as resomelagon is in Phase 2 work for rheumatoid arthritis and viral inflammation, including dengue.
tags
instruments
sources
- SynAct Pharma AB (publ) (SYNACT) Gets US Patent Allowance for Resomelagon Tablet — TradingView, 13 November 2026 at 07:00 UTC
- SynAct Pharma announces Notice of Allowance of a US patent covering the resomelagon tablet — TradingView, 13 November 2026 at 07:00 UTC
- Synact Pharma Grants US Patent Covering Resomelagon Tablet — Reuters, 13 November 2026 at 07:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗